Drug Trial Radar · NCT02969655
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
Last checked: Nov 19, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
271
Actual
Start
Nov 21, 2016
Primary completion
Jul 2, 2018
Study completion Jul 2, 2018
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Daprodustat is a drug that is currently being developed as a treatment for renal anemia . This study is to evaluate the efficacy and safety of daprodustat following a switch from erythropoiesis-stimulating agent (ESA) in Japanese HD subjects with renal anemia who are currently treated with ESA. The primary objective is to demonstrate non-inferiority of daprodustat to darbepoetin alfa. This study is a 52-week, Phase III, double-blind, active-controlled, parallel-group, multi-center study. The total duration of the study will be approximately 58 weeks including screening and follow-up.
Conditions
- Anaemia
Interventions
Daprodustat smallDrug
Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
Daprodustat small placeboDrug
Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
Daprodustat largeDrug
Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
Daprodustat large placeboDrug
Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
Darbepoetin alfaDrug
Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
Darbepoetin alfa placeboDrug
Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)Time frame: Weeks 40 to 52
Locations
50 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Ehime, Japan
GSK Investigational Site
Ehime, Japan
GSK Investigational Site
Fukui, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukushima, Japan
GSK Investigational Site
Fukushima, Japan
GSK Investigational Site
Gunma, Japan
GSK Investigational Site
Gunma, Japan
GSK Investigational Site
Gunma, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Kagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kyoto, Japan
GSK Investigational Site
Miyagi, Japan
GSK Investigational Site
Nagano, Japan
GSK Investigational Site
Nagano, Japan
GSK Investigational Site
Nagano, Japan
GSK Investigational Site
Okayama, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.